Lymphangiogenesis in the bone–implant interface of orthopedic implants: Importance and consequence
Source abstract
Abstract
Abstract The lymphatic system plays an essential physiological role in homeostasis, interstitial fluid composition, and immunity while impaired lymphatic function has been implicated in a number of pathological conditions, including arthritis and delayed wound healing. This study investigated lymphatic capillary growth and lymphangiogenesis pathways in the bone–implant interface from patients with aseptically loosened prosthetic joints. The newly developed lymphatic specific marker, podoplanin, has enabled the first demonstration of lymphatic capillaries in peri‐prosthetic tissues (60% of cases contained podoplanin positive vessels). The pro‐lymphangiogenic factor (VEGF‐C) and its receptor VEGFR‐3 showed high level of expression in these tissues, (often in areas of high levels of wear debris). However despite the upregulation of the lymphangiogenesis pathway by a VEGF‐C/VEGFR‐3‐mediated mechanism, there were relatively few podoplanin positive lymphatic vessels in the bone–implant interface (3.4% of total vessels). This may have important pathological consequences in terms of perpetuating inflammation and edema by inhibiting the removal of macromolecules, cells, and interstitial fluid. The identification of lymphatic vessels with internalized polyethylene wear particles provides evidence of this route of wear debris transportation to distal sites. This paper highlights the importance of lymphatic vessels in the maintenance of local and distal inflammatory responses to prosthetic wear particles. © 2005 Wiley Periodicals, Inc. J. Biomed. Mater. Res, 2006.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lymphatic System and Diseases · Effects of Vibration on Health · Myofascial pain diagnosis and treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Revision of failed total hip replacement
2. 10.1243/095441197153430410.1243/0954411971534304 ↗
3. 10.2106/00004623-198365050-0000110.2106/00004623-198365050-00001 ↗
4. 10.1016/S0002-9440(10)61765-810.1016/S0002-9440(10)61765-8 ↗
5. 10.1097/01.sla.0000133355.48672.2210.1097/01.sla.0000133355.48672.22 ↗
6. 10.1111/j.1749-6632.2002.tb04871.x10.1111/j.1749-6632.2002.tb04871.x ↗
7. 10.1007/BF0033255310.1007/BF00332553 ↗
8. Vascular endothelial growth factors C and D and their VEGFR‐2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium
9. 10.1046/j.1365-2133.1999.02608.x10.1046/j.1365-2133.1999.02608.x ↗
10. 10.1016/S0002-9440(10)65021-310.1016/S0002-9440(10)65021-3 ↗
11. 10.1016/S0002-9440(10)65285-610.1016/S0002-9440(10)65285-6 ↗
12. 10.1083/jcb.144.4.78910.1083/jcb.144.4.789 ↗
13. 10.1016/S0092-8674(00)81511-110.1016/S0092-8674(00)81511-1 ↗
14. 10.1006/mvre.2000.228010.1006/mvre.2000.2280 ↗
15. 10.1016/S0002-9440(10)64035-710.1016/S0002-9440(10)64035-7 ↗
16. 10.1002/j.1460-2075.1996.tb00359.x10.1002/j.1460-2075.1996.tb00359.x ↗
17. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor
18. 10.1242/dev.122.12.382910.1242/dev.122.12.3829 ↗
19. 10.1136/ard.54.3.20110.1136/ard.54.3.201 ↗
20. 10.1023/A:101285842638210.1023/A:1012858426382 ↗
21. 10.1359/jbmr.2003.18.9.157310.1359/jbmr.2003.18.9.1573 ↗
22. Lymphatic vessels in vascularized human corneas: Immunohistochemical investigation using LYVE‐1 and podoplanin
23. 10.2106/00004623-199405000-0001110.2106/00004623-199405000-00011 ↗
24. 10.2106/00004623-200004000-0000210.2106/00004623-200004000-00002 ↗
25. 10.2106/00004623-199604000-0000210.2106/00004623-199604000-00002 ↗
26. 10.1002/(SICI)1097-4636(199602)30:2<157::AID-JBM4>3.0.CO;2-Q10.1002/(SICI)1097-4636(199602)30:2<157::AID-JBM4>3.0.CO;2-Q ↗
27. Cancer risk from orthopedic prostheses
28. 10.1016/S0046-8177(98)90397-510.1016/S0046-8177(98)90397-5 ↗
29. 10.1016/S0883-5403(99)90211-510.1016/S0883-5403(99)90211-5 ↗
30. Oligoclonal T‐cell proliferation and interferon‐gamma production in periprosthetic inflammation
31. Early clinical failure of total joint replacement in association with follicular proliferation of B‐lymphocytes: A report of two cases10.2106/00004623-200212000-00022 ↗
32. 10.1073/pnas.24240139910.1073/pnas.242401399 ↗
33. 10.1016/S1050-1738(02)00189-510.1016/S1050-1738(02)00189-5 ↗
34. 10.1002/path.171146020710.1002/path.1711460207 ↗
35. 10.1007/BF0082202410.1007/BF00822024 ↗
36. 10.1097/00006123-200201000-0002010.1097/00006123-200201000-00020 ↗
37. 10.1016/0163-7258(80)90008-X10.1016/0163-7258(80)90008-X ↗
38. Articular lymphoscintigraphy in human knees using radiolabeled dextran
39. 10.1006/scdb.2001.028610.1006/scdb.2001.0286 ↗
40. 10.1002/jor.110018032210.1002/jor.1100180322 ↗
41. 10.3109/1745367970899669010.3109/17453679708996690 ↗
42. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer
43. 10.1126/science.276.5317.142310.1126/science.276.5317.1423 ↗
44. 10.1093/emboj/20.4.67210.1093/emboj/20.4.672 ↗
45. Lack of lymphangiogenesis despite coexpression of VEGF‐C and its receptor Flt‐4 in uveal melanoma
46. 10.1182/blood-2002-03-075510.1182/blood-2002-03-0755 ↗
47. 10.1016/S0002-9440(10)64255-110.1016/S0002-9440(10)64255-1 ↗
48. 10.1084/jem.194.6.79710.1084/jem.194.6.797 ↗
49. 10.1073/pnas.95.24.1438910.1073/pnas.95.24.14389 ↗
50. 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.0.CO;2-E10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.0.CO;2-E ↗
51. 10.1073/pnas.06204019910.1073/pnas.062040199 ↗